Stay updated with breaking news from Thomas Pfaadt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Product line expanded to include NuCLEANase, an enzyme that has a wide range of potential applications in the food industry The course for future growth has been set: c-LEcta has secured over
Kerry Group acquires majority of the shares of c-LEcta GmbH. The previous management of c-LEcta remains on board. Acquisition promotes c-LEcta's growth potential and allows access to new markets
Leipzig-based biotech company continues on its growth course of past years in 2021 and expects revenue in the range of EUR 20 million Revenue was thus approximately doubled compared to the
c-LEcta Continues Its Growth in 2020 and Increases Its EBITDA Above Average Sales for 2020 to exceed the EUR 10 million mark for the first time EBITDA margin in the double-digit percentage range in 2020 Very strong growth in sales and a further increase in the EBITDA margin expected for 2021 c-LEcta, a globally active biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully continued its growth in 2020 in what turned out to be a challenging year overall. Besides increasing its sales to more than EUR 10 million, an EBITDA margin in the dou...